vs
N-able, Inc.（NABL）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是N-able, Inc.的1.6倍（$207.3M vs $130.3M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 11.8%），N-able, Inc.自由现金流更多（$20.9M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 7.0%）
Able UK是一家英国工业服务企业，主打船舶与海上设施的退役拆解业务，深耕该领域多年，具备大型工业设施拆除作业的专业能力与丰富经验，在英国相关工业服务市场占据一席之地。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
NABL vs RARE — 直观对比
营收规模更大
RARE
是对方的1.6倍
$130.3M
营收增速更快
RARE
高出14.1%
11.8%
自由现金流更多
NABL
多$121.6M
$-100.8M
两年增速更快
RARE
近两年复合增速
7.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $130.3M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | 76.2% | — |
| 营业利润率 | 10.2% | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | 11.8% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $-0.04 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NABLRARE
| Q4 25 | $130.3M | $207.3M | ||
| Q3 25 | $131.7M | $159.9M | ||
| Q2 25 | $131.2M | $166.5M | ||
| Q1 25 | $118.2M | $139.3M | ||
| Q4 24 | $116.5M | $164.6M | ||
| Q3 24 | $116.4M | $139.5M | ||
| Q2 24 | $119.4M | $147.0M | ||
| Q1 24 | $113.7M | $108.8M |
净利润NABLRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $1.4M | $-180.4M | ||
| Q2 25 | $-4.0M | $-115.0M | ||
| Q1 25 | $-7.2M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $10.8M | $-133.5M | ||
| Q2 24 | $9.5M | $-131.6M | ||
| Q1 24 | $7.5M | $-170.7M |
毛利率NABLRARE
| Q4 25 | 76.2% | — | ||
| Q3 25 | 77.5% | — | ||
| Q2 25 | 78.1% | — | ||
| Q1 25 | 76.6% | — | ||
| Q4 24 | 80.0% | — | ||
| Q3 24 | 82.9% | — | ||
| Q2 24 | 84.0% | — | ||
| Q1 24 | 83.9% | — |
营业利润率NABLRARE
| Q4 25 | 10.2% | -54.7% | ||
| Q3 25 | 8.8% | -106.9% | ||
| Q2 25 | 7.7% | -64.8% | ||
| Q1 25 | 1.5% | -102.6% | ||
| Q4 24 | 13.7% | -74.3% | ||
| Q3 24 | 20.5% | -94.6% | ||
| Q2 24 | 18.4% | -79.1% | ||
| Q1 24 | 18.0% | -151.9% |
净利率NABLRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | 1.1% | -112.8% | ||
| Q2 25 | -3.1% | -69.0% | ||
| Q1 25 | -6.1% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 9.2% | -95.7% | ||
| Q2 24 | 7.9% | -89.5% | ||
| Q1 24 | 6.6% | -156.8% |
每股收益（稀释后）NABLRARE
| Q4 25 | $-0.04 | $-1.28 | ||
| Q3 25 | $0.01 | $-1.81 | ||
| Q2 25 | $-0.02 | $-1.17 | ||
| Q1 25 | $-0.04 | $-1.57 | ||
| Q4 24 | $0.01 | $-1.34 | ||
| Q3 24 | $0.06 | $-1.40 | ||
| Q2 24 | $0.05 | $-1.52 | ||
| Q1 24 | $0.04 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $111.8M | $421.0M |
| 总债务越低越好 | $393.9M | — |
| 股东权益账面价值 | $804.7M | $-80.0M |
| 总资产 | $1.4B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.49× | — |
8季度趋势，按日历期对齐
现金及短期投资NABLRARE
| Q4 25 | $111.8M | $421.0M | ||
| Q3 25 | $101.4M | $202.5M | ||
| Q2 25 | $93.9M | $176.3M | ||
| Q1 25 | $94.1M | $127.1M | ||
| Q4 24 | $85.2M | $174.0M | ||
| Q3 24 | $174.4M | $150.6M | ||
| Q2 24 | $157.5M | $480.7M | ||
| Q1 24 | $139.2M | $112.3M |
总债务NABLRARE
| Q4 25 | $393.9M | — | ||
| Q3 25 | $331.7M | — | ||
| Q2 25 | $332.1M | — | ||
| Q1 25 | $332.6M | — | ||
| Q4 24 | $333.1M | — | ||
| Q3 24 | $333.6M | — | ||
| Q2 24 | $334.1M | — | ||
| Q1 24 | $334.5M | — |
股东权益NABLRARE
| Q4 25 | $804.7M | $-80.0M | ||
| Q3 25 | $813.4M | $9.2M | ||
| Q2 25 | $809.4M | $151.3M | ||
| Q1 25 | $775.1M | $144.2M | ||
| Q4 24 | $759.3M | $255.0M | ||
| Q3 24 | $765.0M | $346.8M | ||
| Q2 24 | $724.4M | $432.4M | ||
| Q1 24 | $709.1M | $140.3M |
总资产NABLRARE
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.4B | $1.3B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $1.2B | $1.6B | ||
| Q1 24 | $1.1B | $1.3B |
负债/权益比NABLRARE
| Q4 25 | 0.49× | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.43× | — | ||
| Q4 24 | 0.44× | — | ||
| Q3 24 | 0.44× | — | ||
| Q2 24 | 0.46× | — | ||
| Q1 24 | 0.47× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $20.9M | $-100.8M |
| 自由现金流率自由现金流/营收 | 16.0% | -48.6% |
| 资本支出强度资本支出/营收 | 3.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $75.1M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流NABLRARE
| Q4 25 | $25.3M | $-99.8M | ||
| Q3 25 | $24.0M | $-91.4M | ||
| Q2 25 | $24.2M | $-108.3M | ||
| Q1 25 | $19.7M | $-166.5M | ||
| Q4 24 | $26.0M | $-79.3M | ||
| Q3 24 | $22.0M | $-67.0M | ||
| Q2 24 | $27.3M | $-77.0M | ||
| Q1 24 | $4.2M | $-190.7M |
自由现金流NABLRARE
| Q4 25 | $20.9M | $-100.8M | ||
| Q3 25 | $17.4M | $-92.7M | ||
| Q2 25 | $20.4M | $-110.7M | ||
| Q1 25 | $16.4M | $-167.8M | ||
| Q4 24 | $18.8M | $-79.5M | ||
| Q3 24 | $18.2M | $-68.6M | ||
| Q2 24 | $24.0M | $-79.0M | ||
| Q1 24 | $746.0K | $-193.9M |
自由现金流率NABLRARE
| Q4 25 | 16.0% | -48.6% | ||
| Q3 25 | 13.2% | -58.0% | ||
| Q2 25 | 15.5% | -66.5% | ||
| Q1 25 | 13.9% | -120.5% | ||
| Q4 24 | 16.2% | -48.3% | ||
| Q3 24 | 15.7% | -49.2% | ||
| Q2 24 | 20.1% | -53.7% | ||
| Q1 24 | 0.7% | -178.2% |
资本支出强度NABLRARE
| Q4 25 | 3.4% | 0.5% | ||
| Q3 25 | 5.0% | 0.8% | ||
| Q2 25 | 2.9% | 1.5% | ||
| Q1 25 | 2.8% | 1.0% | ||
| Q4 24 | 6.1% | 0.1% | ||
| Q3 24 | 3.2% | 1.2% | ||
| Q2 24 | 2.7% | 1.4% | ||
| Q1 24 | 3.0% | 3.0% |
现金转化率NABLRARE
| Q4 25 | — | — | ||
| Q3 25 | 17.36× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.04× | — | ||
| Q2 24 | 2.89× | — | ||
| Q1 24 | 0.56× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NABL
| Transferred Over Time | $121.9M | 94% |
| Transferred At Point In Time | $8.4M | 6% |
| Other Revenue | $1.3M | 1% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
